COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

News and Announcements

All | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Displaying 1 - 20 of 230
CPTAC Announces New PCC, PGDAC, and PTRC Teams

This month, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, has reaffirmed its commitment to furthering proteogenomics research by announcing the next round of Proteome Characterization Center (PCC; RFA-CA-21...


NCI Welcomes Renewed Commitments to the Cancer Moonshot with Japan and the Republic of Korea

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of three separate collaborations with Japan and the Republic of Korea (ROK), affirming the two countries’ commitment to international cancer research and care, expanding efforts in the emerging...


Proteogenomic Characterization of In vivo Protein Complexes via Chemical Cross-Linking and Mass Spectrometry

Protein complexes are a fundamental component of physiological and pathological processes. Despite organisms having a limited number of genes and therefore a finite number of proteins at their disposal, the number of possible combinations amongst these proteins is essentially inexhaustible; myriad...


Young Scientist Highlight: Aniket Dagar

The following is the transcript of an interview conducted to highlight promising undergraduate student researcher Aniket Dagar from University of Michigan. Aniket was recently awarded a meritorious poster award for the poster he presented at the 2022 American Association for Cancer Research (AACR)...


CPTAC Glycoproteomic Researchers Develop "Peptide-First" Multi-Attribute Glycan Identification Method

Glycosylation is critical for a wide range of biological processes and is implicated in numerous diseases. Analysis of the glycoproteome has the potential to reveal a wealth of clinical insights, but the heterogeneity of glycosylation makes this analysis difficult. Because of the analytical...


Machine Learning-Derived Metrics Enable Computational Method Comparison in Phosphoproteomics Research

Protein phosphorylation dysregulation has been recognized as a key feature of several diseases, especially cancer. In recent years, phosphoproteomic research has revealed novel, effective biomarkers and drug targets for disease prognosis and treatment. Tandem mass spectrometry (MS/MS)-based...


Proteogenomics Provides New Insights into Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (iCCA) is the second-most common primary liver tumor and has a low 5-year survival rate of 15%. Treatment of iCCA is particularly difficult due to its markedly aggressive progression, late symptom presentation, and early metastasis. In order to improve...


CPTAC Researchers Identify CPT1A as a Potential Therapeutic Target in Platinum-Refractory, High-Grade Serous Ovarian Cancer Patients

At present, typical treatment for patients with high-grade serous ovarian cancer (HGSOC) is surgical debulking coupled with platinum-based chemotherapy. Despite the majority of HGSOCs being sensitive to platinum-based therapy initially, most become resistant over the course of treatment. The...


CPTAC Researchers Detect Fraud in Large-Scale Molecular Omics Datasets with Exceptional Accuracy Using Machine Learning

Modern computational tools for data collection and analysis have revolutionized how scientists are able to research and respond to problems. While the growing number of large, public data sets is a great boon for researchers, the accessibility of these resources can introduce quality and security...


CPTAC Researchers Develop a Novel, Targeted Mass Spectrometry Assay Panel that Enables Quantification of Immunomodulatory Proteins

Immunotherapies are revolutionizing modern cancer care, but at present, many technologies do not accurately quantify the myriad soluble proteins in the tumor microenvironment which impact immunity. This, in turn, contributes to the pervasiveness of patient resistance and immune-related adverse events...


The Human Melanoma Proteome Atlas: Proteogenomic Researchers Map Protein Expression in Malignant Melanoma

Earlier this year, a team from the European Cancer Moonshot Lund Center at Lund University published proteomics and corresponding proteogenomic integration studies for malignant melanomas (MM). The twin publications represent an effort to map protein...


CPTAC Researchers Produce a Highly Annotated, Publicly Accessible Database of Genes Associated with Platinum Resistance in Cancer

According to U.S. National Cancer Institute estimates, approximately 10–20% of all cancer patients will receive a platinum drug over the course of their treatment. Cisplatin, the first platinum-based anti-cancer therapy, was approved by the Food and Drug Administration (FDA) for...


Memorandum of Understanding signed by NCI, FDA and HRSA to bring cancer diagnostic devices closer to patients, particularly members of medically underserved and geographically isolated communities

On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient...


Machine Learning Predicts Molecular Features of Endometrial Cancer with Exceptionally High Accuracy

The CPTAC research group led by Dr. David Fenyö at NYU Langone Medical Center has demonstrated the feasibility of a machine learning image processing tool designed to assist pathologists classifying endometrial cancer. Their customized multi-resolution deep convolutional neural network (CNN) model...


Proteogenomics Provides New Insights into Pancreatic Ductal Adenocarcinoma

Despite advances in the efficacy and specificity of cancer treatments over the last decade, pancreatic cancer remains one of the leading causes of death worldwide. The most common type of pancreatic tumor, Pancreatic Ductal Adenocarcinoma (PDAC), has distinctly poor patient outcomes due to its...


A More Complete Molecular Picture of Lung Squamous Cell Carcinoma Comes into View

Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung...


CPTAC Develops HER-2 Targeted Mass Spec Test (CLIA-certified)

In the era of precision medicine, human epidermal growth factor receptor 2 (HER2) is one of the important predictive and prognostic biomarkers in breast cancer. At present, conventional HER2-targeting therapies improve outcomes for patients with HER2-positive breast cancer, defined as tumors having...


Study Finds Clues to Why Some Kidney Cancers Respond to Treatment While Others Do Not

Kidney cancer is the eighth most diagnosed cancer for both men and women in the United States, and about 76,000 new cases and nearly 14,000 deaths are expected in 2021. It is a category that includes many different kinds of cancer and is dominated by renal cell carcinoma.


AML Microenvironment Catalyzes a Step-wise Evolution to Gilteritinib Resistance

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. It is characterized by an aberrant proliferation of immature myeloblasts that infiltrate the bone marrow and impair normal hematopoiesis. AML is the most common type of acute leukemia in adults and usually worsens quickly if...


Multiplexed Assays to Monitor Your Oncogenic Growth Signaling Network

In the age of personalized cancer therapy, genetic sequencing technologies allow clinicians to rapidly pinpoint mutations likely involved in driving patient-specific tumorigenesis and disease progression. These oncogenic mutations lead to the aberrant activation of signaling pathways involved in...


Pages